<Cites Bologa, C., et al. 2005>

1. Masek, B. B., Shen, L., Smith, K. M., & Pearlman, R. S. (2008). Sharing chemical information without sharing chemical structure. Journal of Chemical Information and Modeling, 48(2), 256-261.

<Cites Rosen, H., et al. 2005>

2. Allende, M. L., Zhou, D., Kalkofen, D. N., Benhamed, S., Tuymetova, G., & Borowski, C. et al. (2008). S1P1 receptor expression regulates emergence of NKT cells in peripheral tissues. FASEB Journal, 22(1), 307-315.

3. Anada, Y., Igarashi, Y., & Kihara, A. (2007). The immunomodulator FTY720 is phosphorylated and released from platelets. European Journal of Pharmacology, 568(1-3), 106-111.

4. Awad, A. S., Ye, H., Huang, L., Li, L., Foss Jr., F. W., & Macdonald, T. L. et al. (2006). Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney. American Journal of Physiology - Renal Physiology, 290(6), F1516-F1524.

5. Baran, Y., Salas, A., Senkal, C. E., Gunduz, U., Bielawski, J., & Obeid, L. M. et al. (2007). Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. Journal of Biological Chemistry, 282(15), 10922-10934.

6. Baumruker, T., Billich, A., & Brinkmann, V. (2007). FTY720, an immunomodulatory sphingolipid mimetic: Translation of a novel mechanism into clinical benefit in multiple sclerosis. Expert Opinion on Investigational Drugs, 16(3), 283-289.

7. Beaven, M. A. (2007). Division of labor: Specialization of sphingosine kinases in mast cells. Immunity, 26(3), 271-273.

8. Bot, M., Nofer, J. -., van Berkel, T. J. C., & Biessen, E. A. L. (2007). Lysophospholipids: Two-faced mediators in atherosclerosis. Future Lipidology, 2(3), 341-356.

9. Brinkmann, V. (2007). Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacology and Therapeutics, 115(1), 84-105.

10. Brinkmann, V., & Baumruker, T. (2006). Pulmonary and vascular pharmacology of sphingosine 1-phosphate. Current Opinion in Pharmacology, 6(3), 244-250.

11. Cahalan, M. D., & Gutman, G. A. (2006). The sense of place in the immune system. Nature Immunology, 7(4), 329-332.

12. Cahalan, M. D., & Parker, I. (2006). Imaging the choreography of lymphocyte trafficking and the immune response. Current Opinion in Immunology, 18(4), 476-482.

13. Cassan, C., Piaggio, E., Zappulla, J. P., Mars, L. T., Couturier, N., & Bucciarelli, F. et al. (2006). Pertussis toxin reduces the number of splenic Foxp3+ regulatory T cells. Journal of Immunology, 177(3), 1552-1560.

14. Catarzi, S., Giannoni, E., Favilli, F., Meacci, E., Iantomasi, T., & Vincenzini, M. T. (2007). Sphingosine 1-phosphate stimulation of NADPH oxidase activity: Relationship with platelet-derived growth factor receptor and c-src kinase. Biochimica et Biophysica Acta - General Subjects, 1770(6), 872-883.

15. Cattaneo, M. G., Chini, B., & Vicentini, L. M. (2008). Oxytocin stimulates migration and invasion in human endothelial cells. British Journal of Pharmacology, 153(4), 728-736.

16. Chalfant, C. E., & Spiegel, S. (2005). Sphingosine 1-phosphate and ceramide 1-phosphate: Expanding roles in cell signaling. Journal of Cell Science, 118(20), 4605-4612.

17. Chiyo, M., Iwata, T., Webb, T. J., Vasko, M. R., Thompson, E. L., Heidler, K. M., et al. (2008). Silencing S1P1 receptors regulates collagen-V reactive lymphocyte-mediated immunobiology in the transplanted lung. American Journal of Transplantation, 8(3), 537-546.

18. Cinamon, G., Zachariah, M. A., Lam, O. M., Foss Jr., F. W., & Cyster, J. G. (2008). Follicular shuttling of marginal zone B cells facilitates antigen transport. Nature Immunology, 9(1), 54-62.

19. Cohen, J., Sundar, K., & Bleich, D. (2007). Pathogenesis of type 1 diabetes: Regulation of adhesion molecules and immune cell trafficking. Current Immunology Reviews, 3(2), 87-100.

20. Coisne, C., Lyck, R., & Engelhardt, B. (2007). Therapeutic targeting of leukocyte trafficking across the blood-brain barrier. Inflammation and Allergy - Drug Targets, 6(4), 210-222.

21. Dalmasso, G., Cottrez, F., Imbert, V., Lagadec, P., Peyron, J. -., & Rampal, P. et al. (2006). Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. Gastroenterology, 131(6), 1812-1825.

22. Donati, C., & Bruni, P. (2006). Sphingosine 1-phosphate regulates cytoskeleton dynamics: Implications in its biological response. Biochimica et Biophysica Acta - Biomembranes, 1758(12), 2037-2048.

23. Duan, H. -., Wang, H., Yi, J., Liu, H. -., Zhang, Q. -., & Li, L. -. et al. (2007). Adenoviral gene transfer of sphingosine kinase 1 protects heart against ischemia/reperfusion-induced injury and attenuates its postischemic failure. Human Gene Therapy, 18(11), 1119-1128.

24. Durand, C. A., Westendorf, J., Tse, K. W. K., & Gold, M. R. (2006). The rap GTPases mediate CXCL13- and sphingosine 1-phosphate-induced chemotaxis, adhesion, and Pyk2 tyrosine phosphorylation in B lymphocytes. European Journal of Immunology, 36(8), 2235-2249.

25. El Alwani, M., Wu, B. X., Obeid, L. M., & Hannun, Y. A. (2006). Bioactive sphingolipids in the modulation of the inflammatory response. Pharmacology and Therapeutics, 112(1), 171-183.

26. Friese, M. A., Montalban, X., Willcox, N., Bell, J. I., Martin, R., & Fugger, L. (2006). The value of animal models for drug development in multiple sclerosis. Brain, 129(8), 1940-1952.

27. Fukunaga, K., Arita, M., Takahashi, M., Morris, A. J., Pfeffer, M., & Levy, B. D. (2006). Identification and functional characterization of a presqualene diphosphate phosphatase. Journal of Biological Chemistry, 281(14), 9490-9497.

28. Gallo, A. P., Silva, L. B. L., Franco, M., Burdmann, E. A., & Bueno, V. (2006). Tacrolimus in combination with FTY720 - an analysis of renal and blood parameters. International Immunopharmacology, 6(11), 1723-1728.

29. Garg, S. K., Santucci, M. B., Panitti, M., Pucillo, L., Bocchino, M., & Okajima, F. et al. (2006). Does sphingosine 1-phosphate play a protective role in the course of pulmonary tuberculosis? Clinical Immunology, 121(3), 260-264.

30. Giussani, P., Maceyka, M., Le Stunff, H., Mikami, A., Lépine, S., & Wang, E. et al. (2006). Sphingosine-1-phosphate phosphohydrolase regulates endoplasmic reticulum-to-golgi trafficking of ceramide. Molecular and Cellular Biology, 26(13), 5055-5069.

31. Goldacker, S., Draeger, R., Warnatz, K., Huzly, D., Salzer, U., & Thiel, J. et al. (2007). Active vaccination in patients with common variable immunodeficiency (CVID). Clinical Immunology, 124(3), 294-303.

32. Gullick, N., & D’Cruz, D. (2007). New therapies for the treatment of systemic lupus erythematosus. Expert Opinion on Therapeutic Patents, 17(3), 299-313.

33. Hait, N. C., Bellamy, A., Milstien, S., Kordula, T., & Spiegel, S. (2007). Sphingosine kinase type 2 activation by ERK-mediated phosphorylation. Journal of Biological Chemistry, 282(16), 12058-12065.

34. Hänel, P., Andréani, P., & Gräler, M. H. (2007). Erythrocytes store and release sphingosine 1-phosphate in blood. FASEB Journal, 21(4), 1202-1209.

35. Hashimoto, D., Asakura, S., Matsuoka, K. -., Sakoda, Y., Koyama, M., & Aoyama, K. et al. (2007). FTY720 enhances the activation-induced apoptosis of donor T cells and modulates graft-versus-host disease. European Journal of Immunology, 37(1), 271-281.

36. Hemmer, B., & Hartung, H. -. (2007). Toward the development of rational therapies in multiple sclerosis: What is on the horizon? Annals of Neurology, 62(4), 314-326.

37. Horga, A., & Montalban, X. (2008). FTY720 (fingolimod) for relapsing multiple sclerosis. Expert Review of Neurotherapeutics, 8(5), 699-714.

38. Idzko, M., Hammad, H., Van Nimwegen, M., Kool, M., Müller, T., & Soullié, T. et al. (2006). Local application of FTY720 to the lung abrogates experimental asthma by altering dendritic cell function. Journal of Clinical Investigation, 116(11), 2935-2944.

39. Itagaki, K., Yun, J. K., Hengst, J. A., Yatani, A., Hauser, C. J., & Spolarics, Z. et al. (2007). Sphingosine 1-phosphate has dual functions in the regulation of endothelial cell permeability and Ca2+ metabolism. Journal of Pharmacology and Experimental Therapeutics, 323(1), 186-191.

40. Jiang, L. I., Collins, J., Davis, R., Lin, K. -., DeCamp, D., & Roach, T. et al. (2007). Use of a cAMP BRET sensor to characterize a novel regulation of cAMP by the sphingosine 1-phosphate/G13 pathway. Journal of Biological Chemistry, 282(14), 10576-10584.

41. Jiang, X., & Han, X. (2006). Characterization and direct quantitation of sphingoid base-1-phosphates from lipid extracts: A shotgun lipidomics approach. Journal of Lipid Research, 47(8), 1865-1873.

42. Jin, Z. -., & Karliner, J. S. (2006). Low dose N, N-dimethylsphingosine is cardioprotective and activates cytosolic sphingosine kinase by a PKCε dependent mechanism. Cardiovascular Research, 71(4), 725-734.

43. Jo, S. -., Bajwa, A., Awad, A. S., Lynch, K. R., & Okusa, M. D. (2008). Sphingosine-1-phosphate receptors: Biology and therapeutic potential in kidney disease. Kidney International, 73(11), 1220-1230.

44. Jun, D. -., Lee, J. -., Choi, B. -., Koh, T. -., Ha, D. -., & Jeong, M. -. et al. (2006). Sphingosine-1-phosphate modulates both lipolysis and leptin production in differentiated rat white adipocytes. Endocrinology, 147(12), 5835-5844.

45. Kabashima, K., Haynes, N. M., Xu, Y., Nutt, S. L., Allende, M. L., & Proia, R. L. et al. (2006). Plasma cell S1P1 expression determines secondary lymphoid organ retention versus bone marrow tropism. Journal of Experimental Medicine, 203(12), 2683-2690.

46. Kajimoto, T., Okada, T., Yu, H., Goparaju, S. K., Jahangeer, S., & Nakamura, S. -. (2007). Involvement of sphingosine-1-phosphate in glutamate secretion in hippocampal neurons. Molecular and Cellular Biology, 27(9), 3429-3440.

47. Keul, P., Sattler, K., & Levkau, B. (2007). HDL and its sphingosine-1-phosphate content in cardioprotection. Heart Failure Reviews, 12(3-4), 301-306.

48. Keul, P., Tölle, M., Lucke, S., Von Wnuck Lipinski, K., Heusch, G., & Schuchardt, M. et al. (2007). The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 27(3), 607-613.

49. Kieseier, B. C., Wiendl, H., Hemmer, B., & Hartung, H. -. (2007). Treatment and treatment trials in multiple sclerosis. Current Opinion in Neurology, 20(3), 286-293.

50. Kihara, A., Mitsutake, S., Mizutani, Y., & Igarashi, Y. (2007). Metabolism and biological functions of two phosphorylated sphingolipids, sphingosine 1-phosphate and ceramide 1-phosphate. Progress in Lipid Research, 46(2), 126-144.

51. Kinashi, T. (2007). Integrin regulation of lymphocyte trafficking: Lessons from structural and signaling studies.

52. Klatt, J., Hartung, H. -., & Hohlfeld, R. (2007). FTY720 (fingolimod) as a new therapeutic option for multiple sclerosis. Nervenarzt, 78(10), 1200-1208.

53. Klawitter, S., Hofmann, L. P., Pfeilschifter, J., & Huwiler, A. (2007). Extracellular nucleotides induce migration of renal mesangial cells by upregulating sphingosine kinase-1 expression and activity. British Journal of Pharmacology, 150(3), 271-280.

54. Kleinschnitz, C., Meuth, S. G., Kieseier, B. C., & Wiendl, H. (2007). Immunotherapeutic approaches in MS: Update on pathophysiology and emerging agents or strategies 2006. Endocrine, Metabolic and Immune Disorders - Drug Targets, 7(1), 35-63.

55. Kleinschnitz, C., Meuth, S. G., Stüve, O., Kieseier, B., & Wiendl, H. (2007). Multiple sclerosis therapy: An update on recently finished trials. Journal of Neurology, 254(11), 1473-1490.

56. Klingenberg, R., Nofer, J. -., Rudling, M., Bea, F., Blessing, E., & Preusch, M. et al. (2007). Sphingosine-1-phosphate analogue FTY720 causes lymphocyte redistribution and hypercholesterolemia in ApoE-deficient mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 27(11), 2392-2399.

57. Kolter, T., & Sandhoff, K. (2006). Sphingolipid metabolism diseases. Biochimica et Biophysica Acta - Biomembranes, 1758(12), 2057-2079.

58. Kraal, G., & Mebius, R. (2006). New insights into the cell biology of the marginal zone of the spleen. International Review of Cytology, 250, 175-215.

59. Kuehn, H. S., & Gilfillan, A. M. (2007). G protein-coupled receptors and the modification of FcεRI-mediated mast cell activation. Immunology Letters, 113(2), 59-69.

60. Kunisawa, J., Kurashima, Y., Gohda, M., Higuchi, M., Ishikawa, I., & Miura, F. et al. (2007). Sphingosine 1-phosphate regulates peritoneal B-cell trafficking for subsequent intestinal IgA production. Blood, 109(9), 3749-3756.

61. Kunisawa, J., Kurashima, Y., Higuchi, M., Gohda, M., Ishikawa, I., & Ogahara, I. et al. (2007). Sphingosine 1-phosphate dependence in the regulation of lymphocyte trafficking to the gut epithelium. Journal of Experimental Medicine, 204(10), 2335-2348.

62. Kunwar, P. S., Siekhaus, D. E., & Lehmann, R. (2006). In vivo migration: A germ cell perspective.

63. Lahiri, S., & Futerman, A. H. (2007). The metabolism and function of sphingolipids and glycosphingolipids. Cellular and Molecular Life Sciences, 64(17), 2270-2284.

64. Lai, L. -., Yong, K. -., Igarashi, S., & Lien, Y. -. H. (2007). A sphingosine-1-phosphate type 1 receptor agonist inhibits the early T-cell transient following renal ischemia-reperfusion injury. Kidney International, 71(12), 1223-1231.

65. Lan, Y. Y., De Creus, A., Colvin, B. L., Abe, M., Brinkmann, V., & Coates, P. T. H. et al. (2005). The sphingosine-1-phosphate receptor agonist FTY720 modulates dendritic cell trafficking in vivo. American Journal of Transplantation, 5(11), 2649-2659.

66. Landeen, L. K., Aroonsakool, N., Haga, J. H., Hu, B. S., & Giles, W. R. (2007). Sphingosine-1-phosphate receptor expression in cardiac fibroblasts is modulated by in vitro culture conditions. American Journal of Physiology - Heart and Circulatory Physiology, 292(6), H2698-H2711.

67. Lee, J. -., Ozaki, H., Zhan, X., Wang, E., Hla, T., & Lee, M. -. (2006). Sphingosine-1-phosphate signaling regulates lamellipodia localization of cortactin complexes in endothelial cells. Histochemistry and Cell Biology, 126(3), 297-304.

68. Lichte, K., Rossi, R., Danneberg, K., Braak, M. T., Kürschner, U., Jakobs, K. H., et al. (2008). Lysophospholipid receptor-mediated calcium signaling in human keratinocytes. Journal of Investigative Dermatology, 128(6), 1487-1498.

69. Lien, Y. -. H., Yong, K. -., Cho, C., Igarashi, S., & Lai, L. -. (2006). S1P1-selective agonist, SEW2871, ameliorates ischemic acute renal failure. Kidney International, 69(9), 1601-1608.

70. Lu, X., & Bittman, R. (2006). Enantioselective synthesis of the phosphate esters of the immunosuppressive lipid FTY720. Tetrahedron Letters, 47(5), 825-827.

71. Luster, A. D., Alon, R., & von Andrian, U. H. (2005). Immune cell migration in inflammation: Present and future therapeutic targets. Nature Immunology, 6(12), 1182-1190.

72. Maeda, Y., Matsuyuki, H., Shimano, K., Kataoka, H., Sugahara, K., & Chiba, K. (2007). Migration of CD4 T cells and dendritic cells toward sphingosine 1-phosphate (S1P) is mediated by different receptor subtypes: S1P regulates the functions of murine mature dendritic cells via S1P receptor type 3. Journal of Immunology, 178(6), 3437-3446.

73. Maines, L. W., French, K. J., Wolpert, E. B., Antonetti, D. A., & Smith, C. D. (2006). Pharmacologic manipulation of sphingosine kinase in retinal endothelial cells: Implications for angiogenic ocular diseases. Investigative Ophthalmology and Visual Science, 47(11), 5022-5031.

74. Mansoor, M., & Melendez, A. J. (2008). Recent trials for FTY720 (fingolimod): A new generation of immunomodulators structurally similar to sphingosine. Reviews on Recent Clinical Trials, 3(1), 62-69.

75. Martini, S., Peters, H., Böhler, T., & Budde, K. (2007). Current perspectives on FTY720. Expert Opinion on Investigational Drugs, 16(4), 505-518.

76. Massberg, S., Schaerli, P., Knezevic-Maramica, I., Köllnberger, M., Tubo, N., & Moseman, E. A. et al. (2007). Immunosurveillance by hematopoietic progenitor cells trafficking through blood, lymph, and peripheral tissues. Cell, 131(5), 994-1008.

77. Massberg, S., & Von Andrian, U. H. (2006). Fingolimod and sphingosine-1-phosphate - modifiers of lymphocyte migration. New England Journal of Medicine, 355(11), 1088-1091.

78. McCandless, E. E., & Klein, R. S. (2007). Molecular targets for disrupting leukocyte trafficking during multiple sclerosis. Expert Reviews in Molecular Medicine, 9(20), 1-19.

79. Medina-Tato, D. A., Watson, M. L., & Ward, S. G. (2006). Leukocyte navigation mechanisms as targets in airway diseases. Drug Discovery Today, 11(19-20), 866-879.

80. Melendez, A. J. (2008). Sphingosine kinase signalling in immune cells: Potential as novel therapeutic targets. Biochimica et Biophysica Acta - Proteins and Proteomics, 1784(1), 66-75.

81. Metzler, B., Gfeller, P., Wieczorek, G., Li, J., Nuesslein-Hildesheim, B., Katopodis, A., et al. (2008). Modulation of T cell homeostasis and alloreactivity under continuous FTY720 exposure. International Immunology, 20(5), 633-644.

82. Meyer zu Heringdorf, D., & Jakobs, K. H. (2007). Lysophospholipid receptors: Signalling, pharmacology and regulation by lysophospholipid metabolism. Biochimica et Biophysica Acta - Biomembranes, 1768(4), 923-940.

83. Mitra, P., Oskeritzian, C. A., Payne, S. G., Beaven, M. A., Milstien, S., & Spiegel, S. (2006). Role of ABCC1 in export of sphingosine-1-phosphate from mast cells. Proceedings of the National Academy of Sciences of the United States of America, 103(44), 16394-16399.

84. Myat, L. O., Thangada, S., Wu, M. -., Liu, C. H., Macdonald, T. L., & Lynch, K. R. et al. (2007). Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. Journal of Biological Chemistry, 282(12), 9082-9089.

85. Nixon, G. F., Mathieson, F. A., & Hunter, I. (2008). The multi-functional role of sphingosylphosphorylcholine. Progress in Lipid Research, 47(1), 62-75.

86. Nofer, J. -., Bot, M., Brodde, M., Taylor, P. J., Salm, P., & Brinkmann, V. et al. (2007). FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation, 115(4), 501-508.

87. Novgorodov, A. S., El-Alwani, M., Bielawski, J., Obeid, L. M., & Gudz, T. I. (2007). Activation of sphingosine-1-phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration. FASEB Journal, 21(7), 1503-1514.

88. Ogretmen, B. (2006). Sphingolipids in cancer: Regulation of pathogenesis and therapy. FEBS Letters, 580(23), 5467-5476.

89. Okamoto, N., Chihara, R., Shimizu, C., Nishimoto, S., & Watanabe, T. (2007). Artificial lymph nodes induce potent secondary immune responses in naive and immunodeficient mice. Journal of Clinical Investigation, 117(4), 997-1007.

90. Olivera, A., Mizugishi, K., Tikhonova, A., Ciaccia, L., Odom, S., & Proia, R. L. et al. (2007). The sphingosine kinase-sphingosine-1-phosphate axis is a determinant of mast cell function and anaphylaxis. Immunity, 26(3), 287-297.

91. Oskeritzian, C. A., Milstien, S., & Spiegel, S. (2007). Sphingosine-1-phosphate in allergic responses, asthma and anaphylaxis. Pharmacology and Therapeutics, 115(3), 390-399.

92. Pan, C. -., Wu, A. Z., & Chen, Y. -. (2007). Lysophospholipids regulate excitability and exocytosis in cultured bovine chromaffin cells. Journal of Neurochemistry, 102(3), 944-956.

93. Pappu, R., Schwab, S. R., Cornelissen, I., Pereira, J. P., Regard, J. B., & Xu, Y. et al. (2007). Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science, 316(5822), 295-298.

94. Payne, S. G., Oskeritzian, C. A., Griffiths, R., Subramanian, P., Barbour, S. E., & Chalfant, C. E. et al. (2007). The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors. Blood, 109(3), 1077-1085.

95. Pébay, A., Bonder, C. S., & Pitson, S. M. (2007). Stem cell regulation by lysophospholipids. Prostaglandins and Other Lipid Mediators, 84(3-4), 83-97.

96. Pham, T. -. T., Kriwacki, R. W., & Parrill, A. L. (2007). Peptide design and structural characterization of a GPCR loop mimetic. Biopolymers, 86(4), 298-310.

97. Pi, X., Tan, S. -., Hayes, M., Xiao, L., Shayman, J. A., & Ling, S. et al. (2006). Sphingosine kinase 1-mediated inhibition of fas death signaling in rheumatoid arthritis B lymphoblastoid cells. Arthritis and Rheumatism, 54(3), 754-764.

98. Renault, A. D., & Lehmann, R. (2006). Follow the fatty brick road: Lipid signaling in cell migration. Current Opinion in Genetics and Development, 16(4), 348-354.

99. Rivera, J., & Olivera, A. (2007). Src family kinases and lipid mediators in control of allergic inflammation. Immunological Reviews, 217(1), 255-268.

100. Rivera, R., & Chun, J. (2007). Potential therapeutic roles of lysophospholipid signaling in autoimmune-related disease. Future Lipidology, 2(5), 535-545.

101. Ryan, J. J., & Spiegel, S. (2008). The role of sphingosine-1-phosphate and its receptors in asthma. Drug News and Perspectives, 21(2), 89-96.

102. Sabourdy, F., Kedjouar, B., Sorli, S. C., Colié, S., Milhas, D., Salma, Y., et al. (2008). Functions of sphingolipid metabolism in mammals - lessons from genetic defects. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 1781(4), 145-183.

103. Salmi, M., & Jalkanen, S. (2005). Cell-surface enzymes in control of leukocyte trafficking. Nature Reviews Immunology, 5(10), 760-771.

104. Santucci, M. B., Greco, E., De Spirito, M., Arcovito, G., De Angelis, G., & Cauda, R. et al. (2007). Sphingosine 1-phosphate promotes antigen processing and presentation to CD4+ T cells in mycobacterium tuberculosis-infected monocytes. Biochemical and Biophysical Research Communications, 361(3), 687-693.

105. Sarkar, S., Maceyka, M., Hait, N. C., Paugh, S. W., Sankala, H., & Milstien, S. et al. (2005). Sphingosine kinase 1 is required for migration, proliferation and survival of MCF-7 human breast cancer cells. FEBS Letters, 579(24), 5313-5317.

106. Sawicka, E., Dubois, G., Jarai, G., Edwards, M., Thomas, M., & Nicholls, A. et al. (2005). The sphingosine 1-phosphate receptor agonist FTY720 differentially affects the sequestration of CD4+/CD25+ T-regulatory cells and enhances their functional activity. Journal of Immunology, 175(12), 7973-7980.

107. Schultz, C. (2006). Lipid-induced phenotypes. Nature Chemical Biology, 2(8), 396-398.

108. Schwab, S. R., & Cyster, J. G. (2007). Finding a way out: Lymphocyte egress from lymphoid organs. Nature Immunology, 8(12), 1295-1301.

109. Schwab, S. R., Pereira, J. P., Matloubian, M., Xu, Y., Huang, Y., & Cyster, J. G. (2005). Immunology: Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science, 309(5741), 1735-1739.

110. Ségui, B., Andrieu-Abadie, N., Jaffrézou, J. -., Benoist, H., & Levade, T. (2006). Sphingolipids as modulators of cancer cell death: Potential therapeutic targets. Biochimica et Biophysica Acta - Biomembranes, 1758(12), 2104-2120.

111. Serriere-Lanneau, V., Teixeira-Clerc, F., Li, Y., Schippers, M., De Wries, W., & Julien, B. et al. (2007). The sphingosine 1-phosphate receptor S1P2 triggers hepatic wound healing. FASEB Journal, 21(9), 2005-2013.

112. Siffrin, V., Brandt, A. U., Herz, J., & Zipp, F. (2007). New insights into adaptive immunity in chronic neuroinflammation.

113. Singh, I. N., & Hall, E. D. (2008). Multifaceted roles of sphingosine-1-phosphate: How does this bioactive sphingolipid fit with acute neurological injury? Journal of Neuroscience Research, 86(7), 1419-1433.

114. Sitkiewicz, I., Stockbauer, K. E., & Musser, J. M. (2007). Secreted bacterial phospholipase A2 enzymes: Better living through phospholipolysis. Trends in Microbiology, 15(2), 63-69.

115. Snook, C. F., Jones, J. A., & Hannun, Y. A. (2006). Sphingolipid-binding proteins. Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, 1761(8), 927-946.

116. Spiegel, S., & Milstien, S. (2007). Functions of the multifaceted family of sphingosine kinases and some close relatives. Journal of Biological Chemistry, 282(4), 2125-2129.

117. Sung, H. K., Min, J. C., Chang, H. L., & Sang, G. K. (2007). Gα12 specifically regulates COX-2 induction by sphingosine 1-phosphate: Role for JNK-dependent ubiquitination and degradation of IκBα. Journal of Biological Chemistry, 282(3), 1938-1947.

118. Tan, S. -., Xiao, L., Pi, X., & Holoshitz, J. (2007). Aberrant gi protein coupled receptor-mediated cell survival signaling in rheumatoid arthritis B cell lines. Frontiers in Bioscience, 12(5), 1651-1660.

119. Vachal, P., Toth, L. M., Hale, J. J., Yan, L., Mills, S. G., & Chrebet, G. L. et al. (2006). Highly selective and potent agonists of sphingosine-1-phosphate 1 (S1P1) receptor. Bioorganic and Medicinal Chemistry Letters, 16(14), 3684-3687.

120. Vestweber, D., & Wild, M. K. (2008). A new player in lymphocyte homing. Nature Immunology, 9(4), 347-348.

121. Walzer, T., Chiossone, L., Chaix, J., Calver, A., Carozzo, C., & Garrigue-Antar, L. et al. (2007). Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor. Nature Immunology, 8(12), 1337-1344.

122. Ward, S. G. (2006). T lymphocytes on the move: Chemokines, PI 3-kinase and beyond. Trends in Immunology, 27(2), 80-87.

123. Wattenberg, B. W., Pitson, S. M., & Raben, D. M. (2006). The sphingosine and diacylglycerol kinase superfamily of signaling kinases: Localization as a key to signaling function. Journal of Lipid Research, 47(6), 1128-1139.

124. Wiedmaier, N., Müller, S., Köberle, M., Manncke, B., Krejci, J., Autenrieth, I. B., et al. (2008). Bacteria induce CTGF and CYR61 expression in epithelial cells in a lysophosphatidic acid receptor-dependent manner. International Journal of Medical Microbiology, 298(3-4), 231-243.

125. Won, J., & Lee, G. H. (2008). T-cell-targeted signaling inhibitors. International Reviews of Immunology, 27(1-2), 19-41.

126. Wymann, M. P., & Schneiter, R. (2008). Lipid signaling in disease. Nature Reviews Molecular Cell Biology, 9(2), 162-176.

127. Yopp, A. C., Ledgerwood, L. G., Ochando, J. C., & Bromberg, J. S. (2006). Sphingosine 1-phosphate receptor modulators: A new class of immunosuppressants. Clinical Transplantation, 20(6), 788-795.

128. Young, N., & Van Brocklyn, J. R. (2006). Signal transduction of sphingosine-1-phosphate G protein-coupled receptors. TheScientificWorldJournal, 6, 946-966.

129. Yu, X. -., & Anasetti, C. (2007). FTY720 prevents GVHD: The host perspective. Blood, 110(9), 3094.

130. Zhang, Y. H., Fehrenbacher, J. C., Vasko, M. R., & Nicol, G. D. (2006). Sphingosine-1-phosphate via activation of a G-protein-coupled receptor(s) enhances the excitability of rat sensory neurons. Journal of Neurophysiology, 96(3), 1042-1052.

131. Zhang, Y. H., Vasko, M. R., & Nicol, G. D. (2006). Intracellular sphingosine 1-phosphate mediates the increased excitability produced by nerve growth factor in rat sensory neurons. Journal of Physiology, 575(1), 101-113.

132. Zhao, Y., Kalari, S. K., Usatyuk, P. V., Gorshkova, I., He, D., & Watkins, T. et al. (2007). Intracellular generation of sphingosine 1-phosphate in human lung endothelial cells: Role of lipid phosphate phosphatase-1 and sphingosine kinase. Journal of Biological Chemistry, 282(19), 14165-14177.

<Cites Wei, S., et al. 2005>

133. Allende, M. L., Zhou, D., Kalkofen, D. N., Benhamed, S., Tuymetova, G., & Borowski, C. et al. (2008). S1P1 receptor expression regulates emergence of NKT cells in peripheral tissues. FASEB Journal, 22(1), 307-315.

134. Bajénoff, M., Egen, J. G., Koo, L. Y., Laugier, J., Brau, F., & Glaichenhaus, N. et al. (2006). Stromal cell networks regulate lymphocyte entry, migration, and territoriality in lymph nodes. Immunity, 25(6), 989-1001.

135. Beltman, J. B., Marée, A. F. M., Lynch, J. N., Miller, M. J., & De Boer, R. J. (2007). Lymph node topology dictates T cell migration behavior. Journal of Experimental Medicine, 204(4), 771-780.

136. Beyer, T., & Meyer-Hermann, M. (2008). Mechanisms of organogenesis of primary lymphoid follicles. International Immunology, 20(4), 615-623.

137. Bot, M., Nofer, J. -., van Berkel, T. J. C., & Biessen, E. A. L. (2007). Lysophospholipids: Two-faced mediators in atherosclerosis. Future Lipidology, 2(3), 341-356.

138. Brinkmann, V., & Baumruker, T. (2006). Pulmonary and vascular pharmacology of sphingosine 1-phosphate. Current Opinion in Pharmacology, 6(3), 244-250.

139. Ceballos, A., Sabatté, J., Nahmod, K., Martínez, D., Salamone, G., & Vermeulen, M. et al. (2007). Sphingosylphosphorylcholine activates dendritic cells, stimulating the production of interleukin-12. Immunology, 121(3), 328-336.

140. Cheon, S., Song, S. B., Jung, M., Park, Y., Bang, J. -., Kim, T. S., et al. (2008). Sphingosine kinase inhibitor suppresses IL-18-induced interferon-gamma production through inhibition of p38 MAPK activation in human NK cells. Biochemical and Biophysical Research Communications, 374(1), 74-78.

141. Cooke, N., & Zécri, F. (2007). Chapter 16 sphingosine 1-phosphate type 1 receptor modulators: Recent advances and therapeutic potential.

142. Cyster, J. G. (2007). Specifying the patterns of immune cell migration

143. Dev, K. K., Mullershausen, F., Mattes, H., Kuhn, R. R., Bilbe, G., & Hoyer, D. et al. (2008). Brain sphingosine-1-phosphate receptors: Implication for FTY720 in the treatment of multiple sclerosis. Pharmacology and Therapeutics, 117(1), 77-93.

144. Dudek, S. M., Camp, S. M., Chiang, E. T., Singleton, P. A., Usatyuk, P. V., & Zhao, Y. et al. (2007). Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor. Cellular Signalling, 19(8), 1754-1764.

145. Dustin, M. L., & Chakraborty, A. K. (2008). Tug of war at the exit door. Immunity, 28(1), 15-17.

146. Friese, M. A., Montalban, X., Willcox, N., Bell, J. I., Martin, R., & Fugger, L. (2006). The value of animal models for drug development in multiple sclerosis. Brain, 129(8), 1940-1952.

147. Germain, R. N., Miller, M. J., Dustin, M. L., & Nussenzweig, M. C. (2006). Dynamic imaging of the immune system: Progress, pitfalls and promise. Nature Reviews Immunology, 6(7), 497-507.

148. Gollmann, G., Neuwirt, H., Tripp, C. H., Mueller, H., Konwalinka, G., Heufler, C., et al. (2008). Sphingosine-1-phosphate receptor type-1 agonism impairs blood dendritic cell chemotaxis and skin dendritic cell migration to lymph nodes under inflammatory conditions. International Immunology, 20(7), 911-923.

149. Gray, N. S. (2006). Drug discovery through industry-academic partnerships. Nature Chemical Biology, 2(12), 649-653.

150. Hänel, P., Andréani, P., & Gräler, M. H. (2007). Erythrocytes store and release sphingosine 1-phosphate in blood. FASEB Journal, 21(4), 1202-1209.

151. Herzinger, T., Kleuser, B., Schäfer-Korting, M., & Korting, H. C. (2007). Sphingosine-1-phosphate signaling and the skin. American Journal of Clinical Dermatology, 8(6), 329-336.

152. Hickman, H. D., Takeda, K., Skon, C. N., Murray, F. R., Hensley, S. E., & Loomis, J. et al. (2008). Direct priming of antiviral CD8+ T cells in the peripheral interfollicular region of lymph nodes. Nature Immunology, 9(2), 155-165.

153. Hla, T., Venkataraman, K., & Michaud, J. (2008). The vascular S1P gradient-cellular sources and biological significance. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 1781(9), 477-482.

154. Holz, L. E., McCaughan, G. W., Benseler, V., Bertolino, P., & Bowen, D. G. (2008). Liver tolerance and the manipulation of immune outcomes. Inflammation and Allergy - Drug Targets, 7(1), 6-18.

155. Horga, A., & Montalban, X. (2008). FTY720 (fingolimod) for relapsing multiple sclerosis. Expert Review of Neurotherapeutics, 8(5), 699-714.

156. Huang, J. H., Cárdenas-Navia, L. I., Caldwell, C. C., Plumb, T. J., Radu, C. G., & Rocha, P. N. et al. (2007). Requirements for T lymphocyte migration in explanted lymph nodes. Journal of Immunology, 178(12), 7747-7755.

157. Huwiler, A., & Pfeilschifter, J. (2008). New players on the center stage: Sphingosine 1-phosphate and its receptors as drug targets. Biochemical Pharmacology, 75(10), 1893-1900.

158. Idzko, M., Hammad, H., Van Nimwegen, M., Kool, M., Müller, T., & Soullié, T. et al. (2006). Local application of FTY720 to the lung abrogates experimental asthma by altering dendritic cell function. Journal of Clinical Investigation, 116(11), 2935-2944.

159. Im, D. -. (2007). Lysophospholipase D/autotaxin in lysophospholipid biology. Current Enzyme Inhibition, 3(1), 13-17.

160. Kabashima, K., Haynes, N. M., Xu, Y., Nutt, S. L., Allende, M. L., & Proia, R. L. et al. (2006). Plasma cell S1P1 expression determines secondary lymphoid organ retention versus bone marrow tropism. Journal of Experimental Medicine, 203(12), 2683-2690.

161. Kahan, B. D. (2008). Frontiers in immunosuppression. Transplantation Proceedings, 40(1), 11-15.

162. Keller, C. D., Gil, P. R., Tölle, M., Van Der Giet, M., Chun, J., & Radeke, H. H. et al. (2007). Immunomodulator FTY720 induces myofibroblast differentiation via the lysophospholipid receptor S1P3 and Smad3 signaling. American Journal of Pathology, 170(1), 281-292.

163. Khanna, K. M., & Lefrançois, L. (2008). Geography and plumbing control the T cell response to infection. Immunology and Cell Biology, 86(5), 416-422.

164. Kihara, A., Mitsutake, S., Mizutani, Y., & Igarashi, Y. (2007). Metabolism and biological functions of two phosphorylated sphingolipids, sphingosine 1-phosphate and ceramide 1-phosphate. Progress in Lipid Research, 46(2), 126-144.

165. Kihara, A., & Igarashi, Y. (2008). Production and release of sphingosine 1-phosphate and the phosphorylated form of the immunomodulator FTY720. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 1781(9), 496-502.

166. Kim, K., Kim, H. -., Lee, Y. -., Han, M., Sacket, S. J., Jo, J. -., et al. (2008). Lysophosphatidylserine induces calcium signaling through Ki16425/VPC32183-sensitive GPCR in bone marrow-derived mast cells and in C6 glioma and colon cancer cells. Archives of Pharmacal Research, 31(3), 310-317.

167. Kunwar, P. S., Siekhaus, D. E., & Lehmann, R. (2006). In vivo migration: A germ cell perspective.

168. Kunwar, P. S., Sano, H., Renault, A. D., Barbosa, V., Fuse, N., & Lehmann, R. (2008). Tre1 GPCR initiates germ cell transepithelial migration by regulating drosophila melanogaster E-cadherin. Journal of Cell Biology, 183(1), 157-168.

169. Ladi, E., Yin, X., Chtanova, T., & Robey, E. A. (2006). Thymic microenvironments for T cell differentiation and selection. Nature Immunology, 7(4), 338-343.

170. Lai, L. -., Yong, K. -., Igarashi, S., & Lien, Y. -. H. (2007). A sphingosine-1-phosphate type 1 receptor agonist inhibits the early T-cell transient following renal ischemia-reperfusion injury. Kidney International, 71(12), 1223-1231.

171. Lämmermann, T., & Sixt, M. (2008). The microanatomy of T-cell responses. Immunological Reviews, 221(1), 26-43.

172. Ledgerwood, L. G., Lal, G., Zhang, N., Garin, A., Esses, S. J., & Ginhoux, F. et al. (2008). The sphingosine 1-phosphate receptor 1 causes tissue retention by inhibiting the entry of peripheral tissue T lymphocytes into afferent lymphatics. Nature Immunology, 9(1), 42-53.

173. Ledgerwood, L. G., & Ochando, J. C. (2007). Leukocyte trafficking in transplantation tolerance: Home sweet home. Inmunologia, 26(1), 42-50.

174. Lee, Y. -., Kim, K., Kim, H. -., Sacket, S. J., Han, M., & Jo, J. -. et al. (2007). Lysophosphatidylserine increases membrane potentials in rat C6 glioma cells. Archives of Pharmacal Research, 30(9), 1096-1101.

175. Ley, K., & Morris, M. (2005). Signals for lymphocyte egress. Nature Immunology, 6(12), 1215-1216.

176. Lynch, K. R., & Macdonald, T. L. (2008). Sphingosine 1-phosphate chemical biology. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 1781(9), 508-512.

177. Mansoor, M., & Melendez, A. J. (2008). Recent trials for FTY720 (fingolimod): A new generation of immunomodulators structurally similar to sphingosine. Reviews on Recent Clinical Trials, 3(1), 62-69.

178. Martino, A. (2007). Sphingosine 1-phosphate as a novel immune regulator of dendritic cells. Journal of Biosciences, 32(6), 1207-1212.

179. Massberg, S., Schaerli, P., Knezevic-Maramica, I., Köllnberger, M., Tubo, N., & Moseman, E. A. et al. (2007). Immunosurveillance by hematopoietic progenitor cells trafficking through blood, lymph, and peripheral tissues. Cell, 131(5), 994-1008.

180. McLachlan, J. B., & Jenkins, M. K. (2007). Migration and accumulation of effector CD4+ T cells in nonlymphoid tissues. Proceedings of the American Thoracic Society, 4(5), 439-442.

181. Metzler, B., Gfeller, P., Wieczorek, G., Li, J., Nuesslein-Hildesheim, B., Katopodis, A., et al. (2008). Modulation of T cell homeostasis and alloreactivity under continuous FTY720 exposure. International Immunology, 20(5), 633-644.

182. Myat, L. O., Thangada, S., Wu, M. -., Liu, C. H., Macdonald, T. L., & Lynch, K. R. et al. (2007). Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. Journal of Biological Chemistry, 282(12), 9082-9089.

183. Nofer, J. -. (2008). High-density lipoprotein, sphingosine 1-phosphate, and atherosclerosis. Journal of Clinical Lipidology, 2(1), 4-11.

184. Nombela-Arrieta, C., Mempel, T. R., Soriano, S. F., Mazo, I., Wymann, M. P., & Hirsch, E. et al. (2007). A central role for DOCK2 during interstitial lymphocyte motility and sphingosine-1-phosphate-mediated egress. Journal of Experimental Medicine, 204(3), 497-510.

185. Ochando, J. C., Ledgerwood, L. G., Yopp, A. C., & Bromberg, J. S. (2006). Trafficking and migration in tolerance. Current Opinion in Organ Transplantation, 11(4), 379-384.

186. Okada, T., & Cyster, J. G. (2007). CC chemokine receptor 7 contributes to gi-dependent T cell motility in the lymph node. Journal of Immunology, 178(5), 2973-2978.

187. Okada, T., & Cyster, J. G. (2006). B cell migration and interactions in the early phase of antibody responses. Current Opinion in Immunology, 18(3), 278-285.

188. Osinde, M., Mullershausen, F., & Dev, K. K. (2007). Phosphorylated FTY720 stimulates ERK phosphorylation in astrocytes via S1P receptors. Neuropharmacology, 52(5), 1210-1218.

189. Oskeritzian, C. A., Milstien, S., & Spiegel, S. (2007). Sphingosine-1-phosphate in allergic responses, asthma and anaphylaxis. Pharmacology and Therapeutics, 115(3), 390-399.

190. Pappu, R., Schwab, S. R., Cornelissen, I., Pereira, J. P., Regard, J. B., & Xu, Y. et al. (2007). Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science, 316(5822), 295-298.

191. Payne, S. G., Oskeritzian, C. A., Griffiths, R., Subramanian, P., Barbour, S. E., & Chalfant, C. E. et al. (2007). The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors. Blood, 109(3), 1077-1085.

192. Pham, T. H. M., Okada, T., Matloubian, M., Lo, C. G., & Cyster, J. G. (2008). S1P1 receptor signaling overrides retention mediated by gαi-coupled receptors to promote T cell egress. Immunity, 28(1), 122-133.

193. Renault, A. D., & Lehmann, R. (2006). Follow the fatty brick road: Lipid signaling in cell migration. Current Opinion in Genetics and Development, 16(4), 348-354.

194. Rivera, J., Proia, R. L., & Olivera, A. (2008). The alliance of sphingosine-1-phosphate and its receptors in immunity. Nature Reviews Immunology, 8(10), 753-763.

195. Ryan, J. J., & Spiegel, S. (2008). The role of sphingosine-1-phosphate and its receptors in asthma. Drug News and Perspectives, 21(2), 89-96.

196. Salomone, S., Potts, E. M., Tyndall, S., Ip, P. C., Chun, J., & Brinkmann, V. et al. (2008). Analysis of sphingosine 1-phosphate receptors involved in constriction of isolated cerebral arteries with receptor null mice and pharmacological tools. British Journal of Pharmacology, 153(1), 140-147.

197. Schultz, C. (2006). Lipid-induced phenotypes. Nature Chemical Biology, 2(8), 396-398.

198. Schwab, S. R., & Cyster, J. G. (2007). Finding a way out: Lymphocyte egress from lymphoid organs. Nature Immunology, 8(12), 1295-1301.

199. Sensken, S. -., Stäubert, C., Keul, P., Levkau, B., Schöneberg, T., & Gräler, M. H. (2008). Selective activation of G alpha i mediated signalling of S1P3 by FTY720-phosphate. Cellular Signalling, 20(6), 1125-1133.

200. Von Wenckstern, H., Zimmermann, K., & Kleuser, B. (2006). The role of the lysophospholipid sphingosine 1-phosphate in immune cell biology. Archivum Immunologiae et Therapiae Experimentalis, 54(4), 239-251.

201. Walzer, T., Chiossone, L., Chaix, J., Calver, A., Carozzo, C., & Garrigue-Antar, L. et al. (2007). Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor. Nature Immunology, 8(12), 1337-1344.

202. Willard-Mack, C. L. (2006). Normal structure, function, and histology of lymph nodes. Toxicologic Pathology, 34(5), 409-424.

203. Worbs, T., Bernhardt, G., & Förster, R. (2008). Factors governing the intranodal migration behavior of T lymphocytes. Immunological Reviews, 221(1), 44-63.

204. Wymann, M. P., & Schneiter, R. (2008). Lipid signalling in disease. Nature Reviews Molecular Cell Biology, 9(2), 162-176.

205.

Yopp, A. C., Ledgerwood, L. G., Ochando, J. C., & Bromberg, J. S. (2006). Sphingosine 1-phosphate receptor modulators: A new class of immunosuppressants. Clinical Transplantation, 20(6), 788-795.